Management of Large Ulcerated Plaque on Inferior Aortic Arch
Start the patient on single antiplatelet therapy (aspirin or clopidogrel) and intensive statin therapy targeting LDL-C <55 mg/dL (<1.4 mmol/L), then assess for high-risk features to determine if intervention is needed. 1
Initial Medical Management
The cornerstone of treatment for aortic arch atheroma is aggressive medical therapy, not routine intervention. The 2024 ESC guidelines are explicit that:
- Single antiplatelet therapy (SAPT) is recommended for secondary prevention in patients with aortic arch atheroma and embolic events 1
- Intensive lipid management to LDL-C <55 mg/dL is recommended to prevent recurrent embolic events 1
- Anticoagulation and dual antiplatelet therapy are NOT recommended as they provide no benefit and increase bleeding risk 1
This represents a critical pitfall to avoid—do not reflexively anticoagulate these patients despite the embolic risk.
Risk Stratification for Intervention
You must now determine if this is a penetrating atherosclerotic ulcer (PAU) requiring intervention. The 2022 ACC/AHA guidelines define high-risk PAU features 2:
High-risk features requiring consideration for intervention:
- PAU diameter ≥13-20 mm
- PAU depth ≥10 mm
- Progressive growth on serial imaging
- PAU associated with saccular aneurysm
- Increasing pleural effusion
Additional high-risk features from research include 3, 4:
- Aortic diameter >42-50 mm at the site
- Symptomatic presentation (chest/back pain)
- Concomitant aortic pathology
Decision Algorithm
If asymptomatic with NO high-risk features:
- Continue medical management
- Serial imaging surveillance with CTA or CMR 1
- Monitor for symptoms or progression
If symptomatic OR has high-risk features:
- Refer urgently to vascular surgery/aortic team for multidisciplinary evaluation 1
- Endovascular repair (TEVAR with branched/fenestrated devices) is first-line if anatomically suitable, with 5% early mortality 3
- Open surgical repair (arch replacement) reserved for younger patients, those unsuitable for endovascular approach, or when durability is paramount 5, 6, 4
The location on the inferior aspect of the arch (likely Ishimaru Zone 2) makes this potentially amenable to endovascular repair with branched devices, though anatomic suitability must be confirmed.
Surveillance Protocol
For conservatively managed patients:
- Repeat CTA or CMR at 3 months initially 7
- Then every 6-12 months depending on stability
- 13% of initially conservatively managed PAUs progress and require intervention 3
Critical Considerations
The inferior arch location is particularly concerning because:
- Ulcerated plaques in the aortic arch carry 5.11-fold higher stroke risk 8
- Multiple brain infarcts occur 7.61-fold more frequently with ulcerated arch plaques 8
- The proximal/transverse arch location (versus distal) has higher embolic potential 9
Age and diabetes are independent risk factors for adverse outcomes with PAU (OR 1.12 and 5.98 respectively) 4, so factor these into your risk assessment.
The key is distinguishing between simple atheroma (medical management only) versus PAU with high-risk features (requires intervention consideration). Obtain dedicated aortic imaging with CTA or CMR to characterize the ulcer dimensions and assess for the high-risk features listed above.